ABADA, PAOLO BENJAMIN,CHANG, SHAO-CHUN,HSU, YANZHI,YANG, LING
申请号：
CA2953576
公开号：
CA2953576A1
申请日:
2015.08.11
申请国别(地区):
CA
年份:
2016
代理人:
摘要：
The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma in patients having levels of alpha-fetoprotein (AFP) of 1.5 ULN or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5 x ULN or greater.
